CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 26 enrolled
Drug / intervention
Freeze Dried Bone Allograft +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03331185
NCT03331185Phase 3Completed
CompareCT.gov

Dimensional Changes of Soft and Hard Tissues Following Alveolar Ridge Preservation: Freeze-dried Bone Allograft vs. L-PRF Clot Covered With d-PTFE Membrane: A Randomized Clinical Trial

University of Manitoba·interventional·Posted Nov 6, 2017·Updated Apr 30, 2020

In Brief

A Phase 3 clinical trial evaluating Freeze Dried Bone Allograft and L-PRF clot for Alveolar Bone Loss and Tooth Loss. Completed, enrolled 26 participants across 1 site.

Detailed Summary

A Clinical Trial to study the effectiveness between two, tooth socket grafting materials namely, Freeze Dried Bone Allograft (human derived bone particles) and Leukocytic-Platelet Rich Fibrin (the patient's own centrifuged blood). The purpose of this study is to compare the effects (good and bad) of Bone Allograft to Platelet Rich Fibrin to see which material would be the most effective in maintaining the volume of the gum and bone of the jaw during the healing phase as well as minimizing the amount of pain and/or swelling following tooth extraction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlveolar Bone Loss, Tooth Loss
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 6, 2017
Enrollment StartJan 3, 2018
Primary CompletionApr 2, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.7 years ago

Interventions

Freeze Dried Bone Allograftbiological

Human derived bone particles used in oral and periodontal grafting procedures

L-PRF clotbiological

L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.